APPENDIX


Inclusion criteria:
All patients who underwent TPB with micro-ultrasound from 2019 (introduction of TPB at our centre) to 2023
And a corresponding consecutive cohort of patients who underwent TRB at our centre between 2019 to 2023
(n=719)
Excluded (n=21)
♦ No pre-biopsy MRI (n=21)
Included in analysis (n=698)
Transrectal biopsy group (n=392)
Transperineal biopsy group (n=306)
Univariable Analysis
Included in primary analysis (n=392)
Included in primary analysis (n=306)
Multivariable Analysis
Analyzed (n=377)
♦ Excluded for missing data (n=15)
Subgroup analyses:
Targeted or combined biopsy (n=222)
♦ Systematic biopsy (n=155)
Excluding active surveillance (n=237)
♦ On AS (n=140)
Biopsy naïve patients (n=145)
♦ Previous biopsy (n=232)
Anterior lesion (n=45)
♦ Other biopsy location (n=49)
♦ Location missing (n=283)
Analyzed (n=262)
♦ Excluded for missing data (n=44)
Subgroup analyses:
Targeted or combined biopsy (n=256)
♦ Systematic biopsy (n=6)
Excluding active surveillance (n=167)
♦ On AS (n=95)
Biopsy naïve patients (n=130)
♦ Previous biopsy (n=132)
Anterior lesion (n=94)
♦ Other biopsy location (n=63)
♦ Location missing (n=105)